Redmile Group, LLC Akero Therapeutics, Inc. Transaction History
Redmile Group, LLC
- $952 Million
- Q1 2025
A detailed history of Redmile Group, LLC transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Redmile Group, LLC holds 939,277 shares of AKRO stock, worth $45 Million. This represents 3.99% of its overall portfolio holdings.
Number of Shares
939,277
Previous 1,235,209
23.96%
Holding current value
$45 Million
Previous $34.4 Million
10.65%
% of portfolio
3.99%
Previous 2.69%
Shares
22 transactions
Others Institutions Holding AKRO
# of Institutions
270Shares Held
86MCall Options Held
1.02MPut Options Held
823K-
Rtw Investments, LP New York, NY7.42MShares$356 Million4.92% of portfolio
-
Janus Henderson Group PLC London, X07.07MShares$339 Million0.16% of portfolio
-
Wellington Management Group LLP Boston, MA5.94MShares$285 Million0.05% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$268 Million0.0% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$251 Million7.15% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $2.22B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...